" class="no-js "lang="en-US"> The Native Antigen Company - Medtech Alert
Wednesday, October 01, 2025
The Native Antigen Company | Pharmtech Focus

The Native Antigen Company

About The Native Antigen Company

The Native Antigen Company

At the Native Antigen Company we are experts in the development and manufacturing of infectious disease antigens from bacteria and viruses, and in the production of recombinant forms of these antigens using our proprietary mammalian expression system.

These antigens are prepared for both research and development purposes, and also on bulk scale for IVD manufacturers to incorporate into their immunoassays.

Our R&D team have particular expertise in flavivirus biology. We were the first in the world to develop mammalian expressed Dengue virus NS1 antigens, and then to develop Zika virus NS1 using the same platform. We have also developed a range of Virus-like particles, which are finding increasing applications as antigens for IVD applications.

We continue to develop cutting edge antigens, and are also now using these antigens to raise highly specific monoclonal antibodies and to develop immunoassays. We also offer these services on a contract basis for customers who need a reliable source of high quality recombinant or native protein.

Related Story

The Native Antigen Company Strengthens Senior Team to Support Growing Product Portfolio

November 24 2022

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers […]

The Native Antigen Company Expands Range of Norovirus-Like Particles

January 13 2022

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of […]